BILLERICA, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet), the leader in tubeless
insulin pump technology with its Omnipod® Insulin
Management System, today announced that management will present at the
36th Annual J.P. Morgan Healthcare Conference in San Francisco,
California on January 9, 2018, at 4:30pm (Pacific Time).
This press release features multimedia. View the full release here:
To listen to a live audio webcast of the presentation, please visit http://investors.insulet.com.
A replay of the webcast will also be available following the event.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, more than
100,000 users across the globe rely on Insulet's Omnipod Insulin
Management System to bring simplicity and freedom to their lives. For
more information, please visit: www.insulet.com,
*Starting July 1, 2018, Insulet will assume direct distribution of its
Omnipod Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This will allow Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it already does in the
United States and Canada.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171220005671/en/
Investor Relations and Media Contact:
Deborah R. Gordon, 978-600-7717
Investor Relations and Corporate Communications
Source: Insulet Corporation
News Provided by Acquire Media